Literature DB >> 2859543

Histaminergic systems and sleep. Studies in man with H1 and H2 antagonists.

A N Nicholson, P A Pascoe, B M Stone.   

Abstract

Effects of H1 (mepyramine, mequitazine, triprolidine and brompheniramine) and H2 (cimetidine and ranitidine) antagonists on sleep were studied in healthy man. There were no effects of mepyramine (50 and 100 mg), and the only effect of mequitazine (5 and 10 mg) was a reduction in the number of awakenings. Triprolidine (10 and 20 mg) and brompheniramine (4 and 8 mg) did not alter wakefulness during sleep or the total sleep time, but rapid eye movement sleep was reduced. There were no effects of ranitidine (150 and 300 mg), but slow wave sleep was increased by cimetidine (200 and 400 mg). It is tentatively suggested that the histaminergic system is concerned with the mechanisms which favour vigilance during the wakeful state, and the balance between wakefulness and slow wave activity during sleep. Effects of some H1 antihistamines on rapid eye movement sleep are believed to be due to their monoaminergic rather than their histaminergic activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859543     DOI: 10.1016/0028-3908(85)90081-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  19 in total

Review 1.  New insights into the second generation antihistamines.

Authors:  G M Walsh; L Annunziato; N Frossard; K Knol; S Levander; J M Nicolas; M Taglialatela; M D Tharp; J P Tillement; H Timmerman
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat.

Authors:  J E Sherin; J K Elmquist; F Torrealba; C B Saper
Journal:  J Neurosci       Date:  1998-06-15       Impact factor: 6.167

3.  Optogenetic-mediated release of histamine reveals distal and autoregulatory mechanisms for controlling arousal.

Authors:  Rhannan H Williams; Melissa J S Chee; Daniel Kroeger; Loris L Ferrari; Eleftheria Maratos-Flier; Thomas E Scammell; Elda Arrigoni
Journal:  J Neurosci       Date:  2014-04-23       Impact factor: 6.167

4.  Effects of a sedative and of a non-sedative H1-antihistamine on the event-related potential (ERP) in normal volunteers.

Authors:  F M Swire; C A Marsden; C Barber; A T Birmingham
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Antihistamines: impaired performance and the tendency to sleep.

Authors:  A N Nicholson; B M Stone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  Clinical management of patients with insomnia. The role of zopiclone.

Authors:  G Hajak; A Rodenbeck
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

7.  Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene.

Authors:  A N Nicholson; P A Pascoe; C Turner; C R Ganellin; P M Greengrass; A F Casy; A D Mercer
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

8.  Does ritanserin, a potent serotonin-S2 antagonist, restore energetic functions during the night?

Authors:  P A Janssen
Journal:  J R Soc Med       Date:  1987-07       Impact factor: 5.344

9.  Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice.

Authors:  Zhi-Li Huang; Takatoshi Mochizuki; Wei-Min Qu; Zong-Yuan Hong; Takeshi Watanabe; Yoshihiro Urade; Osamu Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

10.  Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models.

Authors:  Christelle Anaclet; Régis Parmentier; Koliane Ouk; Gérard Guidon; Colette Buda; Jean-Pierre Sastre; Hidéo Akaoka; Olga A Sergeeva; Masashi Yanagisawa; Hiroshi Ohtsu; Patricia Franco; Helmut L Haas; Jian-Sheng Lin
Journal:  J Neurosci       Date:  2009-11-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.